[False innovations in clinical research].
Pharmaceutical innovation is actually poorer than it seems, largely because of "false" innovations. Various factors help create an image of novelty in the pharmaceutical area. These factors act throughout the research and development process and in the post-marketing stages affecting the selection of study hypotheses, the adoption of the appropriate study methodology, and the interpretation and publication of results. Each of these steps may be diverted from the priority objective of patients' interest and shifted towards to the defence of the drugs companies' commercial interests. Regulators, NHS, physicians and patients must be vigilant to recognise and get rid of false innovations which can prevent the use of more effective and safer drugs and waste resources useful for effective treatments in other areas. Rewarding this lack of innovation discourages research for excellence and reduces the competitiveness of the pharmaceutical industry.
Garattini
Silvio
S
Istituto di Ricerche Farmacologiche Mario Negri, Milano.
Bertele'
Vittorio
V
D035843:Biomedical Research / Q000592:standards / Q000639:trends*; D003132:Commerce; D016265:Conflict of Interest; D017277:Drug Approval; D004345:Drug Industry / Q000592:standards*; D005062:European Union; D006801:Humans; D007449:Investments / Q000941:ethics; D007558:Italy; D005791:Patient Care; D010819:Physician's Role